Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07310901). This is a study registration, not published results. Lead sponsor: Corbus Pharmaceuticals Inc.. Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 254 participants (ACTUAL). Conditions: Obese But Otherwise Healthy Participants. Interventions: DRUG: CRB-913; DRUG: Placebo. Primary outcome measures: Part 1: To evaluate the PK of a single dose of CRB-913 - Cmax , 0 to 48 hours; Part 1: To evaluate the PK of a single dose of CRB-913 - Tmax , 0 to 48 hours; Part 1: To evaluate the PK of a single dose of CRB-913 - T1/2 , 0 to 48 hours; Part 2: To evaluate the safety of CRB-913 - TEAE , Day 1 to 28 days post final dose; Part 2: To evaluate the safety of CRB-913 - AESI , Day 1 to 28 days post final dose. Brief summary: This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.